Viropharma Inc

Viropharma — Investor Presentation (January 2010)

21 slides from Viropharma's investor presentation, Jan 11, 2010

  1. Slide 1: ViroPharma Incorporated: Delivering Innovative Treatments for Life-threatening Diseases

    ViroPharma Incorporated Delivering Innovative Treatments for Life-threatening Diseases ViroPharma Incorporated Delivering Innovative Treatments for Life-threatening Diseases Exhibit 99.2

  2. Slide 2: Slide 2

  3. Slide 3: Forward-looking statements

    This presentation contains certain forward-looking statements that involve risks and uncertainties including statements regarding our financial guidance for 2009 and 2010, our ability to continue to execute a successful launch of Cinryze, our ability to achieve peak year sales projections, our abili

  4. Slide 4: ViroPharma

    VIROPHARMA

  5. Slide 5: Slide 5

  6. Slide 6: ViroPharma

    ViRORHARMA

  7. Slide 7: A Prophylactic Option

    A Prophylactic Option • Only C1-INH indicated for routine prophylaxis • Addresses the underlying cause of the disease • Proven to reduce frequency, number and severity of HAE attacks • Self-Administration unique to Cinryze CINRYZE ™ (C1 Esterase Inhibitor [human])

  8. Slide 8: Prophylaxis vs. Acute Treatment

    Prophylaxis vs. Acute Treatment 2009 2010 2011 Prevalent Population i.e. unique individuals in the US who have the disease 11,059 11,154 11,250 Estimate of diagnosed patients 2,544 2,789 3,150 Number of HAE patients who would receive prescription drug therapy 1,628 1,840 2,142 Potential Prophylactic

  9. Slide 9: Patient Access Made Easy

    Patient Access Made Easy • Individualized case management • Benefits coverage investigations • Reimbursement assistance • Single point of contact for ongoing support and follow up CINRYZE Solutions ™

  10. Slide 10: Impressive U.S. Launch

    Impressive U.S. Launch • Over 400 patients on commercial Cinryze at year end 2009 • Average dosing of 1.7 per week • Significant number of additional patients enrolled into Cinryze Solutions • 218 plans covering at least one patient

  11. Slide 11: Quarterly Cinryze Revenue Growth

    Quarterly Cinryze Revenue Growth * Q4 range denotes 2009 Cinryze Net Sales guidance provided on Monday, January 11, 2010

  12. Slide 12: Scale up Progressing to Plan

    Scale up Progressing to Plan PCP Industrial Scale Equipment In Place Additional Shift Staffed Personnel Trained Begin Production Finished Product (Q2) Equipment In Place Equipment Validated Conformance Lots Made Pre-Filing FDA Meeting 3-Month Stability FDA Filing (Q3) Finished Product (EOY)

  13. Slide 13: Annual Cinryze Revenue Growth

    Annual Cinryze Revenue Growth * 2009 Cinryze Net Sales expected to be near the higher end of the provided range of $90-$95 million * 2010 Cinryze Net Sales Guidance provided January 11, 2010 Estimated Peak Year Sales $350 - Estimated Peak Year Sales $350 - $450M $450M

  14. Slide 14: Vancocin

    Vancocin… • FDA advisory panel conducted in 2009 • Panel supported Q1/Q2 sameness requirement • Continued vigilance into the process • Authorized generic ready for release upon approval of 3 party generic product rd

  15. Slide 15: One Way to Consider Generic Impact

    One Way to Consider Generic Impact * Assumes greater than 3 generic entrants

  16. Slide 16: Strong Financial Results

    Strong Financial Results • Total Products Revenue of $223M • Cinryze Net Sales of $61.3M • Reported Adjusted Net Income of $76M • Increased Cash Position to $289M Financial Results through Q3 2009 Working Capital of $358 of $358 Million * Reconciliation of Adjusted Net Income to GAAP Net Income can

  17. Slide 17: Additional Growth Opportunities

    Additional Growth Opportunities • Cinryze as a Platform for Growth • Business Development • Non-toxigenic C. difficile (NTCD)

  18. Slide 18: Broadening the Cinryze Opportunity

    Broadening the Cinryze Opportunity • Expanded Territorial and Indication Rights • Orphan drug status in EU • Submitted PIP to EMEA • Plan to submit MAA in second half of 2010 • Analyst Day event planned for March • Global Expansion • Formulation Development • Additional Indications

  19. Slide 19: Adding to the Business

    Adding to the Business • Treating serious or life threatening illnesses • High unmet medical needs • Limited commercial infrastructure • Providing both top and bottom line growth We are a Biopharmaceutical Company Focused On: Focused Business Development as Another Engine for Growth

  20. Slide 20: ViroPharma Incorporated: Poised for Growth

    ViroPharma Incorporated Poised for Growth Impressive U.S. Launch Cinryze — Platform for Growth Strong Financial Position

  21. Slide 21: ViroPharma Incorporated: Delivering Innovative Treatments for Life-threatening Diseases

    ViroPharma Incorporated Delivering Innovative Treatments for Life-threatening Diseases ViroPharma Incorporated Delivering Innovative Treatments for Life-threatening Diseases

ViroPharma — Investor Presentation (January 2010) on 6ix